Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.33
- Piotroski Score 3.00
- Grade Buy
- Symbol (OPT)
- Company Opthea Limited
- Price $3.16
- Changes Percentage (-0.94%)
- Change -$0.03
- Day Low $3.09
- Day High $3.23
- Year High $5.45
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $14.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.41
- Trailing P/E Ratio -1.04
- Forward P/E Ratio -1.04
- P/E Growth -1.04
- Net Income $-220,242,105
Income Statement
Quarterly
Annual
Latest News of OPT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Daniel Jones likely to opt for playoff contender once he clears...
Daniel Jones, recently waived by the Giants, is expected to clear waivers and sign a one-year deal with a new team soon. He prefers a playoff contender and had a rocky tenure with the Giants, despite ...
By New York Post | 8 hours ago -
How to watch the Philadelphia Eagles vs. Los Angeles Rams NFL game today: Livestream options, more
The Philadelphia Eagles aim to continue their winning streak against the Los Angeles Rams at SoFi Stadium. Learn how to watch the game without cable via NBC, Peacock, and NFL+ subscriptions. Explore f...
By CBS News | 12 hours ago -
How to watch the Dallas Cowboys vs. Washington Commanders NFL game today: Livestream options, more
Get ready for the Dallas Cowboys vs. Washington Commanders game today. Cowboys aim to bounce back from a losing streak while Commanders seek to end their own....
By CBS News | 12 hours ago
